Cellectis has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.11, which signifies a somewhat significant risk relative to the market. Cellectis returns are very sensitive to returns on the market. As the market goes up or down, Cellectis is expected to follow. Cellectis SA right now shows a risk of 5.62%. Please confirm Cellectis SA downside variance, and the relationship between the sortino ratio and accumulation distribution , to decide if Cellectis SA will be following its price patterns.
Risk-Adjusted Performance
Soft
Weak
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Cellectis SA are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating essential indicators, Cellectis may actually be approaching a critical reversion point that can send shares even higher in February 2026. ...more
If you would invest 430.00 in Cellectis SA on October 8, 2025 and sell it today you would earn a total of 10.00 from holding Cellectis SA or generate 2.33% return on investment over 90 days. Cellectis SA is currently generating 0.1922% in daily expected returns and assumes 5.6221% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than Cellectis, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Given the investment horizon of 90 days Cellectis is expected to generate 7.5 times more return on investment than the market. However, the company is 7.5 times more volatile than its market benchmark. It trades about 0.03 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.11 per unit of risk.
Cellectis Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cellectis' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cellectis SA, and traders can use it to determine the average amount a Cellectis' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0342
Best Portfolio
Best Equity
Good Returns
Average Returns
Small Returns
CLLS
Cash
Small Risk
Average Risk
High Risk
Huge Risk
Negative Returns
Based on monthly moving average Cellectis is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cellectis by adding it to a well-diversified portfolio.
Cellectis Fundamentals Growth
Cellectis Stock prices reflect investors' perceptions of the future prospects and financial health of Cellectis, and Cellectis fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cellectis Stock performance.
Assessing Cellectis' fundamental ratios provides investors with valuable insights into Cellectis' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cellectis is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 294 people.
Things to note about Cellectis SA performance evaluation
Checking the ongoing alerts about Cellectis for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cellectis SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Cellectis SA had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 41.51 M. Net Loss for the year was (36.7 M) with profit before overhead, payroll, taxes, and interest of 82.55 M.
Cellectis SA has a frailfinancial position based on the latest SEC disclosures
Evaluating Cellectis' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Cellectis' stock performance include:
Analyzing Cellectis' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cellectis' stock is overvalued or undervalued compared to its peers.
Examining Cellectis' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Cellectis' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cellectis' management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Cellectis' stock. These opinions can provide insight into Cellectis' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Cellectis' stock performance is not an exact science, and many factors can impact Cellectis' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.